Camber Pharmaceuticals is pleased to announce that it has added 

 to their current portfolio, which is the generic version of Neurontin®

 are used together with other medicines to treat partial seizures in adults and children at least 3 years old.

 from Camber are available in 600 and 800 mg strengths in 100 and 500 bottle counts.

To find out more about Gabapentin Tablets please visit http://www.camberpharma.com

Camber Pharmaceuticals is a fully integrated international pharmaceutical company that maintains quality and integrity in all its products. Its parent company, Hetero Drugs of Hyderabad India, is one of the world’s leading API and finished dosage manufacturers. Camber’s commitment to the consumer is to bring the highest quality generic pharmaceuticals to the market to improve quality of life through cost-effective medications.

Articles

Gabapentin Tablets are used together with other medicines to treat partial seizures in adults and children at least 3 years old.

Camber Pharma Launches Generic Neurontin

Pharmacy Quality Solutions (PQS), a leading technology provider of pharmacy performance management services, announced a brand refresh including a new visual identity, redesigned logo and website, and refined mission statement. The refresh comes as the company continues expanding its portfolio of patient health outcome measures and support for value-based reimbursement models.

“The mission of PQS is to contribute to a healthier world by driving quality measurement as the pathway to better patient health outcomes,” said PQS CEO Todd Sega. “Our brand refresh reflects our reach to work with like-minded companies and individuals who align with our mission to improve lives.”

This is PQS’ first brand refresh since the company launched in 2013. The new logo symbolizes growing connectivity in the healthcare industry through a core role in quality measurement. The new color palette includes a vibrant gradient of colors and a streamlined font for a more modern look.

“We believe now is the right time to refresh the company’s brand as we’re broadening how we support payers and pharmacies as a healthcare technology company,” says PQS COO, Nancy Chung. “In the past year, we have expanded our team of dedicated members working with a common goal to create products that contribute to healthier lives. We want to share that vision through the brand refresh, and ultimately, with new product features.”

Updates to PQS’ core products, EQUIPP® and accompanying EQUIPP® analytics products and services, are expected to be announced early next year.

About Pharmacy Quality Solutions, Inc. (PQS)

PQS is a healthcare quality improvement company, connecting healthcare payers and providers who value measurement as the pathway to better patient outcomes. Partners of PQS represent nearly 90% of all Medicare Part D lives and 95% of community pharmacies. PQS delivers the quality insights and guidance necessary to support their customers’ efforts to optimize the quality of medication management for their Medicare, Medicaid and commercial populations. PQS’ industry-leading platform, EQUIPP®, provides standardized measurement and reporting on key medication use quality measures and value-based reimbursement programs focused on medication adherence, treatment outcomes and patient safety. For more information on how PQS can support you, please visit 

For further information contact David Simoneaux at 919.767.9544 or dsimoneaux@pharmacyquality.com.

PQS unveils a new visual identity, logo, and company website.

PQS Announces Brand Refresh and Reaffirms Commitment to Improving Patient Outcomes

NO PURCHASE NECESSARY. OPEN ONLY TO LEGAL RESIDENTS OF THE UNITED STATES OF AMERICA, WHO ARE AT LEAST 18 YEARS OLD AT TIME OF ENTRY AND CURRENTLY A PRACTICING PHARMACIST. Void where prohibited by law. This sweepstakes begins on November 15, 2021, at 12:01 a.m. ET and ends on February 28, 2022, at 11:59 p.m. ET (“Promotion Period”). Sponsor’s computer is the official timekeeping device for this Sweepstakes. Enter the Sweepstakes during the Promotion Period by: (1) reading through the survey invitation e-mail; (2) clicking on the link found in the e-mail, which will take reader to an online survey; (3) completing the online survey; (4) completing the entry form with all required information which will include full name, e-mail address, title, employer, mailing address, phone number, and date of birth; (5) checking the box indicating agreement with these Official Rules; and (6) submitting the entry form pursuant to the on-screen instructions. Online entries must be received no later than 11:59 p.m. ET on February 28, 2022. Alternatively, any currently practicing pharmacist may enter the Sweepstakes by printing the words “2022 OTC Guide Survey,” along with his or her full name, title, date of birth, street address, city, state, zip, and phone number on a 3" by 5" white index card. Mail the card to Pharmacy and Healthcare Communications, LLC, Attn: 2021 OTC Guide Survey, 2 Clarke Drive, Suite 100, Cranbury, NJ 08512. To be considered eligible, entries must be received by 11:59 p.m. ET on February 28, 2022. No methods of entry other than the methods specifically described herein will be accepted. Sponsor is not responsible for lost, late, misdirected, or incomplete entries or unsuccessful attempts to enter. Incomplete entries and/or entries not received by the deadline will not be eligible. Limit (1) one entry per person, per mailing address, per outer mailing envelope, and per e-mail address.

Winner will be selected on or about March 15, 2022, in a random drawing from among all eligible entries received. Drawing will be conducted by Pharmacy and Healthcare Communications, LLC, whose decisions are final. Drawing times are subject to change or cancellation with or without notice. Odds of winning will depend upon the total number of eligible entries received. For winner’s name, send a separate self-addressed, stamped envelope to 2 Clarke Drive, Suite 100, Cranbury, NJ 08512, by September 15, 2022.

The prizes (“Prizes”) consists of one (1) Visa Gift Card, with Approximate Retail Value (“ARV”) of $250.00. 

 All costs and expenses associated with Prize acceptance and use not specified herein as being provided such as reservation fees, taxes, insurance, cellular charges, gratuities, and other expenses incurred by accepting the Prize are the sole responsibility of the Winner. Winner is responsible for paying any necessary State and Federal taxes related to the winnings. Winner may receive an IRS Form 1099 for the retail value of Prize. Visa is a registered trademark of Visa Inc. All rights reserved. Visa does not participant in or sponsor this Sweepstakes.

The limit is one winner for each Prize. Winners will be notified by phone, e-mail, overnight delivery, or first-class mail, as Sponsor shall determine. If a Winner does not respond to Prize Notification as directed within five (5) days of the attempted notification date or if Prize or Prize notification is returned as unclaimed or undeliverable, such Winner will be disqualified, Prize will be forfeited, and an alternate winner will be selected from all remaining eligible entries in a similar random drawing. Upon disqualification, the Prize will be forfeited, and no compensation will be given. Prize is not transferable. No cash or prize substitutions, except the sponsor reserves the right to substitute prizes of equal or greater value. Acceptance of Prize constitutes permission to use that winner's name, likeness, photo, and home town for promotional and publicity purposes in any media now known or later developed, worldwide, at no additional compensation unless prohibited by law. By participating and accepting Prize, Winner releases and agrees to hold harmless Pharmacy and Healthcare Communications, LLC, U.S. News & World Report, L.P., and their respective parent companies, subsidiaries, affiliates, service agencies, sponsors, and any independent contractors of claims of any kind arising in whole or in part, directly or indirectly, from acceptance, possession, use, or misuse of Prize or the participation in this Sweepstakes or any sweepstakes-related activity.

This sweepstakes is open only to legal residents of the United States of America, who are at least 18 years of age at the time of entry and currently a practicing pharmacist. Winner’s eligibility is subject to verification by Sponsor. Void where prohibited by law. All federal, state, and local laws and regulations apply. Persons in any of the following categories are not eligible to participate or win a prize: (a) persons who since January 1, 2016, were or are employees or agents of Pharmacy and Healthcare Communications, LLC, U.S. News & World Report, L.P., or their respective parent company, subsidiaries, affiliates, service agencies, sponsors, and any independent contractors of any kind of the above organizations, including HRA, LLC (the “Administrator”); (b) individuals engaged in the development, production, or distribution of materials or the implementation of the sweepstakes; and (c) employees of the persons in the immediate family of, or persons living in the same household as, any person in any of the preceding categories.

All entries become the property of Sponsor and will not be returned. Information collected by Pharmacy and Healthcare Communications, LLC, in connection with this Sweepstakes may be used by Pharmacy and Healthcare Communications, LLC, and shared with third parties involved in administration of the Sweepstakes. Information collected from entrants is subject to Administrator’s Privacy Policy, available at www.hraresearch.com/privacy-policy. Administrator and Pharmacy and Healthcare, LLC, are responsible solely for their own respective privacy policy and neither Administrator nor Pharmacy and Healthcare Communications, LLC, are responsible for any disclosure made by the other or any third party. Please review Pharmacy and Healthcare Communications, LLC’s, Privacy Policy at www.pharmacytimes.com/privacy. By participating in the Sweepstakes and providing their information, entrants hereby agree to Administrator’s and Pharmacy and Healthcare Communications, LLC’s, collection and usage of their personal information and acknowledge that they have read and accepted the Administrator’s and Pharmacy and Healthcare Communications, LLC’s, Privacy Policies.

Sponsor reserves the right to disqualify any individual found, in its sole opinion, to be tampering with the operation of the Sweepstakes; to be acting in violation of these Official Rules; or to be acting in an unsportsmanlike manner or with the intent to disrupt the normal operation of the Sweepstakes. Any use of robotic, automatic, macro, programmed, third party, or like methods to participate in the Sweepstakes will void any attempted participation affected by such methods and result in the disqualification of the individual utilizing same. CAUTION AND WARNING: ANY ATTEMPT TO DELIBERATELY DAMAGE ANY WEBSITE OR UNDERMINE THE LEGITIMATE OPERATION OF THIS SWEEPSTAKES IS A VIOLATION OF CRIMINAL AND CIVIL LAWS. SHOULD SUCH AN ATTEMPT BE MADE, THE SPONSOR RESERVES THE RIGHT TO SEEK DAMAGES OR OTHER REMEDIES FROM ANY SUCH PERSON(S) RESPONSIBLE FOR THE ATTEMPT TO THE FULLEST EXTENT PERMITTED BY LAW. Sponsor reserves the right to cancel, suspend, and/or modify the Sweepstakes, or any part of it, if any fraud, technical failures, or any other factor beyond Sponsor’s reasonable control impair the integrity or proper functioning of the Sweepstakes, as determined by Sponsor or Administrator in its sole discretion. In such event, Sponsor reserves the right to award the Prize at random from among the eligible entries received up to the time of the impairment. If due to a printing, production, or other error, more prizes are claimed than are intended to be awarded, Prize will be awarded in a random drawing from among all verified and validated entries. In no event will more than one Prize be awarded. In the event of any conflict with any Sweepstakes details contained in these Official Rules and Sweepstakes and details contained in other Sweepstakes-related materials, the details of the Sweepstakes as set forth in these Official Rules shall prevail.

By entering, each entrant agrees for entrant and for entrant’s heirs, executors, and administrators (a) to release and hold harmless Pharmacy and Healthcare Communications, LLC, U.S. News & World Report, L.P., and HRA, LLC, and their respective officers, directors, and employees (collectively, “Released Parties”) from any liability for any illness, injury, death, loss, litigation, or damage that may occur, directly or indirectly, whether caused by negligence or not, from such entrant’s participation in the Sweepstakes and/or his/her acceptance, possession, use, or misuse of Prize or any portion thereof; (b) that Released Parties have neither made nor are in any manner responsible or liable for any warranty, representation, or guarantee, express or implied, in fact or in law, with respect to Prize, including, without limitation, regarding such Prize’s quality or fitness for a particular purpose; and (c) to be bound by these Official Rules and to waive any right to claim any ambiguity or error therein or in the Sweepstakes itself, and to be bound by all decisions of the Sponsor, which are binding and final. Failure to comply with these conditions may result in disqualification from the Sweepstakes at Sponsor’s sole discretion. Sponsor reserves the right to cancel, suspend, and/or modify the Sweepstakes, or any part of it, if any fraud, technical failures, or any other factor beyond Sponsor’s reasonable control impairs the integrity or proper functioning of the Sweepstakes, as determined by Sponsor in its sole discretion. Sponsor makes no warranties, and hereby disclaims any and all warranties, express or implied, concerning any prize furnished in connection with the Sweepstakes. WITHOUT LIMITING THE GENERALITY OF THE FOREGOING, SUCH PRIZES ARE PROVIDED “AS IS” WITHOUT WARRANTY OF ANY KIND, EITHER EXPRESS OR IMPLIED, AND SPONSOR HEREBY DISCLAIMS ALL SUCH WARRANTIES, INCLUDING, BUT NOT LIMITED TO, THE IMPLIED WARRANTIES OF MERCHANTABILITY, FITNESS FOR A PARTICULAR PURPOSE, AND/OR NON-INFRINGEMENT.

This Sweepstakes is subject to all applicable federal, state, and local laws and regulations. Issues concerning the construction, validity, interpretation, and enforceability of these Official Rules shall be governed by the laws of the State of New Jersey, without regard to any principles of conflict of laws. All disputes arising out of or connected with this Sweepstakes will be resolved individually, and without resort to class action, exclusively by a state or federal court located in Middlesex County, New Jersey. Should there be a conflict between the laws of the State of New Jersey and any other laws, the conflict will be resolved in favor of the laws of the State of New Jersey. To the extent permitted by applicable law, all judgments or awards shall be limited to actual out-of-pocket damages (excluding attorneys’ fees) associated with participation in this Sweepstakes and shall not include any indirect, punitive, incidental, and/or consequential damages.

The Sponsor of this Sweepstakes is Pharmacy and Healthcare Communications, LLC, 2 Clarke Drive, Suite 100, Cranbury, NJ 08512. The Administrator of this Sweepstakes is HRA, LLC, 2 Clarke Drive, Suite 100, Cranbury, NJ 08512.

2022 OTC GUIDE SURVEY OFFICIAL RULES PhMg

 to their current portfolio, which is the generic version of Samsca®

 are used to treat hyponatremia (low levels of sodium in your blood) in people with heart failure, and certain hormonal imbalances.

Tolvaptan 30 mg Tablets from Camber are available in 30 mg strength in a 10 (1x10) unit dose blister pack.

To find out more about Tolvaptan 30 mg please visit 

Camber Pharma Launches Generic Samsca

® is pleased to announce that four new organizations have joined its Strategic Alliance Partnership (SAP) program.

"The addition of four prominent partners to our SAP program offers an exciting opportunity to further expand our reach in delivering the latest information within the pharmacy market," said Gil Hernandez, vice president of Pharmacy & Healthcare Communications, LLC, publisher of 

®. "Partnering with each of these organizations helps us work toward our main goal of disseminating the information that will help optimize patient care."

Florida Cancer Specialists & Research Institute:

 Florida Cancer Specialists & Research Institute (FCS) offers patients access to more clinical trials than any private oncology practice in Florida. In the past four years, the majority of new cancer drugs approved for use in the U.S. were studied in clinical trials with Florida Cancer Specialists participation. Founded in 1984, Florida Cancer Specialists has built a national reputation for excellence that is reflected in exceptional and compassionate patient care, driven by innovative clinical research, cutting-edge technologies and advanced treatments, including targeted therapies, genomic-based treatment, and immunotherapy. Their highest values are embodied by their outstanding team of highly trained and dedicated physicians, clinicians and staff.

 is an integrated health system that provides exceptional medical care to local and global communities. Mount Sinai Health System is designed to increase efficiencies and economies of scale, improve quality and outcomes, and expand access to advanced primary, specialty, and ambulatory care services through a wide clinical network.

, since 2012, has been committed to doing what will be most effective to help cancer patients win their fight. As one of the nation's largest cancer physician networks, a community-based approach to patient care is a unique aspect of the organization. Across each of their 25 locations, everything RCCA does is centered around patients' best interest and optimal health.

, one of the nation's leading academic medical centers, forms the centerpiece of the University of Rochester's health research, teaching and patient care missions. As upstate New York's premier health care delivery network, patients benefit from the Medical Center's robust teaching and biomedical research programs. With more than 26,000 employees, URMC works to foster a safe, welcoming, and supportive culture for all.

® is the industry-leading multimedia network of community, health system, oncology, and specialty pharmacy platforms, providing practical clinical and professional information that pharmacists can use in their everyday practice. Each issue of the 

® journal contains articles covering industry trends, drug interactions, patient education, disease state management, patient counseling, product news, pharmacy law, and more. Additionally, 

™ is accredited by the Accreditation Council for Pharmacy Education as a provider of continuing pharmacy education. Pharmacy Times® is a brand of 

Pharmacy Times® is pleased to announce that four new organizations have joined its Strategic Alliance Partnership program.

Pharmacy Times Welcomes Four New Partners to Strategic Alliance Partnership Program

For years, the National Healthcareer Association has advocated on behalf of all pharmacy technicians. Our mission to empower people to access a better future drives us to connect with community pharmacies and other pharmacy technician employers to ensure all techs are granted equal employment opportunities, regardless of their certification.

We're thrilled to announce a new partnership with Walgreens that offers new job opportunities to pharm techs who pass NHA's ExCPT exam.

Effective Nov. 3, 2021, Walgreens started to:

Increase compensation for pharmacy technicians in eligible positions who obtain NHA certification after passing the ExCPT exam

Provide career growth opportunities for certified pharmacy technicians, such as moving into certified technician or senior technician roles

Sponsor eligible technicians to enroll in Walgreens instructor-led certification review sessions and take the ExCPT exam

“Removing barriers that limit the options for certification creates a larger pool of qualified technicians, promotes innovation in the development of training and exam resources, and amplifies the collective voice of industry advocates that support professional advancement for technicians," said Lyndsey McDonald, director at National Healthcareer Association. "We’re proud to further the success of these efforts with this announcement from Walgreens.”

Walgreens is as excited as NHA about this partnership, and they’ve shared the news with their internal teams and store team members. Visit your local Walgreens with any questions about their open technician roles and opportunities for ExCPT-certified technicians.

SOURCE: National Healthcareer Association

CPhT Students and Current Pharm Techs Benefit.

Walgreens Recognizes NHA Pharm Tech Certification

Camber Pharmaceuticals is pleased to announce that it has launched

to their current portfolio, which is the generic version of Capoten®

are used to treat high blood pressure (hypertension), congestive heart failure, kidney problems caused by diabetes, and to improve survival after a heart attack.

Captopril Tablets from Camber are available in 12.5, 25, 50, and 100 mg in 100 count bottles.

Camber Pharma Launches Generic Capoten

, PharmD, FAPhA, FNAP, has been selected by the American Pharmacists Association (APhA) as its liaison representative to the Centers for Disease Control and Infection (CDC) Advisory Committee on Immunization Practices (ACIP).

The ACIP is a group of medical and public health experts that develops recommendations on how to use vaccines to control diseases in the United States.

The CDC sets adult and childhood immunization schedules based on recommendations from the ACIP. The committee considers many factors, including the safety and effectiveness of the vaccine. There are 15 voting members responsible for making vaccine recommendations. The Secretary of the U.S. Department of Health and Human Services (DHHS) selects these members following an application and nomination process. Fourteen of the members have expertise in vaccinology, immunology, pediatrics, internal medicine, nursing, family medicine, virology, public health, infectious diseases, and/or preventive medicine; one member is a consumer representative who provides perspectives on the social and community aspects of vaccination, according to the CDC.

In addition to the 15 voting members, ACIP includes eight ex officio members who represent other federal agencies with responsibility for immunization programs in the United States and 37 non-voting representatives of liaison organizations that bring related immunization expertise to the work of ACIP. Hogue is the second pharmacist to serve on the ACIP. His predecessor served 21 years on the committee.

“We are confident that Dr. Hogue will do an outstanding job in providing his own and pharmacists’ perspectives to the work of ACIP and will be an outstanding contributor to the process,” said Mitchel C. Rothholz, RPh, MBA, APhA chief of governance and state affiliates. “Hogue has actively engaged with CDC and ACIP over the past 25 years and is an active participant as APhA’s appointee to ACIP’s COVID-19 Vaccination Workgroup.”

For the past year and a half, Hogue served as the only pharmacist on ACIP’s COVID-19 vaccine 

. Composed of 45 healthcare professionals, the workgroup meets weekly to establish vaccine efficacy and make policies around the distribution of the vaccine and subsequent booster shots.

Hogue has served in various roles at the McWhorter School of Pharmacy at Samford University College of Health Sciences in Birmingham, Alabama, prior to his time at Loma Linda University, including interim dean, professor, pharmacy practice department chair, and as associate dean for the university’s Center for Faith and Health.

Hogue holds a doctorate of pharmacy from Samford University College of Health Sciences. He is active in the American Association of Colleges of Pharmacy, American Pharmacists Association, and other state and national pharmacy organizations. He served as president of the American Pharmacists Association from 2020 to 2021. Hogue is widely published and has presented at numerous conferences. He has served on several boards, including the National Foundation for Infectious Diseases, the Editorial Advisory Board for the Journal of the American Pharmacists Association, the California Pharmacists Association Foundation, and the California Immunization Coalition. He was inducted into the Alabama Healthcare Hall of Fame in 2018.

Hogue has led Loma Linda University Health’s COVID-19 

 in line with CDC and California state guidelines and has played an integral role in organizing student-based 

Under the direction of Hogue, Loma Linda University School of Pharmacy has been recognized nationally, twice, for the school’s community outreach during the pandemic. LLUSP received the “Rookie Award” at the 10th annual 2021 Medication Adherence 

 from the National Association of Chain Drug Stores (NACDS) Foundation Scholarship Program in September.

Michael Hogue among group that provides vaccine recommendations for US children and adults.

School of Pharmacy Dean Appointed to CDC’s Advisory Committee on Immunization Practices

Camber Pharmaceuticals is pleased to announce it has recently added 4 products to its’ Copay Card Program, which will save patients a substantial amount of money each year. The products include:

“Camber’s Copay Card Program is designed to help patients by increasing access to affordable medicines and improving health outcomes” stated Kon Ostaficiuk, President of Camber.

Numerous studies have shown prescription copayments are a major incentive to drug adherence. In some cases, patients never fill prescriptions or ration medicine or doses to save money.

“Adding these prescriptions to a copay plan makes Camber’s products very attractive to patients and retailers alike. With many prescription drug insurance plans, the patient could have little-to-no copayment,” Kon added.“We hope this brings financial relief to more patients and encourages them follow their healthcare provider’s advice.”

: Deferasirox is used to treat iron overload caused by blood transfusions in adults and children at least 2 years old. Learn more at 

https://www.camberpharma.com/products/deferasirox/

: Dimethyl Fumarate is indicated for the treatment of relapsing forms of multiple sclerosis (MS). Learn more at 

https://www.camberpharma.com/products/dimethyl-fumarate/

: Droxidopa is used to treat symptoms of low blood pressure when standing, caused by a certain medical condition, (neurogenic orthostatic hypotension). Learn more at 

https://www.camberpharma.com/products/droxidopa/

: Vigabatrin is used in combination with other medications to treat seizure disorders. Learn more at 

https://www.camberpharma.com/products/vigabatrin/

For more information about Camber’s copay card program, please visit 

Camber Pharmaceuticals Accelerates Copay Card Program 

Amneal Pharmaceuticals, Inc. (NYSE: AMRX) (“Amneal” or the “Company”) today announced that it is launching dexamethasone, 4mg and 6 mg, following Abbreviated New Drug Application (ANDA) approval from the U.S. Food and Drug Administration (FDA).

Dexamethasone, the generic version of Decadron®, is a well-established anti-inflammatory glucocorticoid steroid used to treat several medical conditions, including respiratory complications associated with COVID-19.

“Today’s approval and launch of dexamethasone reflects the continued execution of our innovation agenda. Expanding access to essential therapies, particularly in the treatment of COVID-19, is core to our mission at Amneal and we are pleased to play our part,” said Chirag and Chintu Patel, Co-Chief Executive Officers.

According to IQVIA™, a leading healthcare data and analytics provider, U.S. annual sales for 4 mg and 6 mg dexamethasone tablets for the 12 months ended August 2021 were approximately $63 million.

Dexamethasone tablets can produce reversible hypothalamic-pituitary adrenal (HPA) axis suppression with the potential for glucocorticosteroid insufficiency. Elevated blood pressure, sodium and water retention, and increased excretion of potassium, have also been reported.

Mild to severe infection with exacerbation may occur with the use of dexamethasone tablets alone or in combination with other immunosuppressive agents. Dexamethasone is contraindicated in patients hypersensitive to any components of this product.

See Package Insert (PI) for full prescribing information including Safety Information: 

https://dailymed.nlm.nih.gov/dailymed/fda/fdaDrugXsl.cfm?setid=ac71f888-c83a-46a5-921c-1ebdf6cfadc1&type=display

Amneal Pharmaceuticals, Inc. (NYSE: AMRX), headquartered in Bridgewater, NJ, is a fully-integrated pharmaceutical company focused on the development, manufacturing and distribution of generic and specialty drug products. The Company has operations in North America, Asia, and Europe, working together to bring high-quality medicines to patients primarily within the United States.

Amneal has an extensive portfolio of approximately 250 product families and is expanding its portfolio to include complex dosage forms, including biosimilars, in a broad range of therapeutic areas. The Company also markets a portfolio of branded pharmaceutical products through its Specialty segment focused principally on central nervous system and endocrine disorders.

The Company also owns 65% of AvKARE. AvKARE provides pharmaceuticals, medical and surgical products and services primarily to governmental agencies, primarily focused on serving the Department of Defense and the Department of Veterans Affairs. AvKARE is also a packager and wholesale distributor of pharmaceuticals and vitamins to its retail and institutional customers who are located throughout the United States focused primarily on offering 340b-qualified entities products to provide consistency in care and pricing. For more information, visit 

Dexamethasone, the generic version of Decadron®, is a well-established anti-inflammatory glucocorticoid steroid used to treat several medical conditions, including respiratory complications associated with COVID-19. 

Press Releases